Galapagos NV (NASDAQ:GLPG) had its price objective upped by Stifel Nicolaus from $101.00 to $120.00 in a report published on Friday, Marketbeat Ratings reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley restated an overweight rating and issued a $92.00 price objective on shares of Galapagos NV in a research note on Thursday, August 10th. Cowen and Company restated a buy rating on shares of Galapagos NV in a research note on Thursday, August 10th. Janney Montgomery Scott upgraded Galapagos NV from a sell rating to a neutral rating in a research note on Friday, July 7th. They noted that the move was a valuation call. BidaskClub upgraded Galapagos NV from a sell rating to a hold rating in a research note on Thursday, August 17th. Finally, Nomura boosted their price objective on Galapagos NV from $108.00 to $124.00 and gave the company a buy rating in a research note on Friday, August 11th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Galapagos NV currently has an average rating of Buy and a consensus target price of $103.71.

Galapagos NV (GLPG) opened at 99.82 on Friday. The company has a 50 day moving average of $101.15 and a 200 day moving average of $97.18. The firm’s market capitalization is $5.08 billion. Galapagos NV has a 1-year low of $57.16 and a 1-year high of $103.54.

WARNING: “Galapagos NV (GLPG) Given New $120.00 Price Target at Stifel Nicolaus” was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/galapagos-nv-glpg-given-new-120-00-price-target-at-stifel-nicolaus/1572485.html.

Several institutional investors and hedge funds have recently made changes to their positions in GLPG. Federated Investors Inc. PA increased its position in shares of Galapagos NV by 36.8% during the second quarter. Federated Investors Inc. PA now owns 1,364,600 shares of the biotechnology company’s stock valued at $104,419,000 after buying an additional 366,800 shares during the period. Renaissance Technologies LLC increased its position in shares of Galapagos NV by 49.5% during the second quarter. Renaissance Technologies LLC now owns 465,300 shares of the biotechnology company’s stock valued at $35,605,000 after buying an additional 154,100 shares during the period. Clough Capital Partners L P increased its position in shares of Galapagos NV by 336.1% during the first quarter. Clough Capital Partners L P now owns 74,870 shares of the biotechnology company’s stock valued at $6,453,000 after buying an additional 57,700 shares during the period. Wellington Management Group LLP increased its position in shares of Galapagos NV by 9.5% during the first quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock valued at $39,483,000 after buying an additional 39,729 shares during the period. Finally, Dorsey Wright & Associates bought a new stake in shares of Galapagos NV during the second quarter valued at about $1,151,000. Hedge funds and other institutional investors own 23.63% of the company’s stock.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.